New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control
Marking the 200th National Meeting of the American Chemical Society, The Division of Nuclear Chemistry and Technology hosted a group of about 90 scientists from 15 different countries to discuss the new trends in radiopharmaceutical synthesis, quality assurance and regulatory control. This event too...
Other Authors: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
New York, NY
Springer US
1991, 1991
|
Edition: | 1st ed. 1991 |
Subjects: | |
Online Access: | |
Collection: | Springer Book Archives -2004 - Collection details see MPG.ReNa |
Table of Contents:
- 1.1 Introductory Remarks
- 1.2 Overview
- 1.3 A Muscarinic Receptor Ligand: Review of the Chemistry and Applications
- 2.1 Aspects on the Synthesis and Design of 11C-Tracers for PET
- 2.2 Special Problems Associated with the Synthesis of High Specific Activity Carbon-11 Labeled Radiotracers
- 2.3 PET Radiopharmaceuticals via Reductive Carboxylation
- 2.4 [13N] Labeled Tracers, Synthesis and Applications
- 2.5 Cu1+ Assisted Nucleophilic Exchange Radiohalogenation: Application and Mechanistic Approach
- 2.6 Potential Breast Tumor Imaging Agents: Fluorotamoxifen and Derivatives
- 2.7 Fluorinated Azabicycloesters as Muscarinic Receptor Ligands for Application with PET
- 2.8 Flourine-18 Ligands for the In Vivo Study of ?-Adrenergic Receptors in the Heart and Lung
- 2.9 Design and Radiofluorination of Benzamide Dopamine D2 Receptor Ligands
- 3.1 A Synthetic Porphyrin with High Affinity for Lung Cancer Cells and Inflamed Lymphatic Tissue
- 7.4 Regulation of Cyclotron Radiopharmaceutical Production and Distribution: An Agreement State Perspective
- 7.5 New Drug Approval Process for Radiopharmaceuticals
- 7.6 Abbreviated New Drug Applications (ANDAS): Future Trends in Radiopharmaceuticals
- 6.2 Quality Assurance Considerations Related to “In-House” Radiopharmaceutical Preparations Utilizing Positron Emitting Radionuclides
- 6.3 The Role of High Performance Liquid Chromatography In Radiochemical/Radiopharmaceutical Synthesis and Quality Assurance
- 6.4 Experience from a National Quality Assurance System on Radiopharmaceuticals
- 6.5 Radiopharmaceutical Production for PET: Quality Assurance Practice, Experience and Issues
- 6.6 Post-Column Reactor Determination of Aluminum Concentration in Cyclotron Produced Radiorubidium
- 6.7 Implications of the Food, Drug and Cosmetic Act on the Quality Assurance of Radiopharmaceuticals used in the United States
- 6.8 Quality Assurance in Radiochemical/Radiopharmaceutical Manufacturing
- 7.1 Regulatory Control ofRadiopharmaceutics
- 7.2 Regulatory Control of Radiopharmaceuticals
- 7.3 Development of European Regulations on Radiopharmaceuticals
- 4.3 The Synthesis of Halogenated Radiopharmaceuticals using Organomercurials
- 4.4 Synthesis of Radiopharmaceuticals Via Organoboranes
- 4.5 Radiosotope Incorporation via Aryl and Alkenyl Trialkyltin Intermediates
- 5.1 Robots In the Radiopharmaceutical Laboratory: Will They Replace the Chemist?
- 5.2 The Use of Transducers for Automated Radiopharmaceutical Synthesis Procedures
- 5.3 Facilitating the Design and Operation of Computer-Controlled Radiochemistry Synthesizers with an “Electronic Toolbox”
- 5.4 Knowledge-Based Automated Radiopharmaceutical Manufacturing for Positron Emission Tomography
- 5.5 Robotic Thin Layer Chromatography Instrument for Synthetic Chemistry
- 5.6 Automated Radiochemical Processing for Clinical PET
- 5.7 Captive Solvent Methods for Fast, Simple, Carbon-11 Radioalkylation
- 6.1 Identity, Strength, Purity, Quality and Safety: Common Goals for New Drugs
- 3.2 Galium and Copper Radiopharmaceutical Chemistry
- 3.3 Radiometallating Antibodies and Autoantigenic Peptides
- 3.4 Biomedical Use of Arsenic Radioisotopes
- 3.5 Improved Extraction Efficiency of Gallium-67 After Irradiation of Zinc-68 with Protons
- 3.6 Chemistry and Concept for An Automated 72Se/72As Generator
- 3.7 Radiochemistry of Monoclonal Antibody Labeling
- 3.8 The Study on the Formulation of A Tc(V)-99m-DMS Lyophilized Instant Kit for Tumor Scintigraphy
- 3.9 A National Biomedical Tracer Facility
- 3.10 Tantalum-178-Labeled Radiopharmaceutical Synthesis Via The Intermediate Tantalum Pentachloride — A Potential Myocardial Perfusion Agent
- 3.11 Status of Lead and Bismuth for Radioimmunoimaging and Therapy
- 4.1 Use of Organolithium and Organomagnesium Reagents In Radiopharmaceutical Synthesis
- 4.2 Application of OrganosiliconChemistry to the Synthesis of Gamma and Positron Emitting Radiotracers for Use In Nuclear Imaging Studies